Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BUSINESS BITES: OrbiMed Launces $950m VC Fund; EKF Casts Off More Loss-Making Ops With Selah Sell-Back; Mela Changes Name

This article was originally published in Clinica

Executive Summary

OrbiMed has closed its biggest venture capital fund to date, raising $950m which it will invest in biopharma, medical devices, diagnostics and healthcare IT companies. It expects to make around 30 investments, in companies based in North America and Europe; each investment will range from $10-75m. Carl Gordon, a partner at OrbiMed and co-head of global private equity, stated: “The increasing pace of translation of science to medicine creates exciting opportunities for the Fund in areas such as oncology, central nervous system disease, and gene editing.” OrbiMed currently has around 40 medtech-related investments in its portfolio, with a strong focus on orthopedics and cardiology among its device companies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT103093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel